What is the P/E ratio of Argent Biopharma 2025?
The P/E ratio cannot be calculated for Argent Biopharma at the moment.
Terminal Access Subscribe for $2
Unlimited access to the most powerful analytical tools in finance.
Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Overview
Profile
Argent Biopharma stock stock price, forecast, news, chart, split, dividend and analysis Argent Biopharma ariva, Argent Biopharma onvista, Argent Biopharma finanzen.net, Argent Biopharma aktienfinder, Argent Biopharma marketscreener, Argent Biopharma marketwatch, Argent Biopharma bloomberg, Argent Biopharma handelsblatt, Argent Biopharma wiwo, Argent Biopharma forum
RGT.AX
AU0000326647
A2ACB6
Price
Price
0
Today +/-
-0
Today %
-0 %
TickerRGT.AX
ISINAU0000326647
WKNA2ACB6
Argent Biopharma stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Argent Biopharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Argent Biopharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Argent Biopharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Argent Biopharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Argent Biopharma Stock Price History
| Date | Argent Biopharma Price |
|---|---|
| 4/25/2025 | 0 undefined |
| 4/24/2025 | 0.15 undefined |
| 4/23/2025 | 0.16 undefined |
| 4/22/2025 | 0.18 undefined |
| 4/17/2025 | 0.18 undefined |
| 4/15/2025 | 0.18 undefined |
| 4/14/2025 | 0.18 undefined |
| 4/11/2025 | 0.18 undefined |
| 4/10/2025 | 0.18 undefined |
| 4/9/2025 | 0.19 undefined |
| 4/8/2025 | 0.18 undefined |
| 4/7/2025 | 0.19 undefined |
| 4/4/2025 | 0.20 undefined |
| 4/3/2025 | 0.20 undefined |
| 4/2/2025 | 0.13 undefined |
| 4/1/2025 | 0.16 undefined |
| 3/31/2025 | 0.17 undefined |
| 3/28/2025 | 0.16 undefined |
Argent Biopharma Revenue, EBIT, Net Income AU0000326647 · A2ACB6
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Argent Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Argent Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Argent Biopharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Argent Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Argent Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Argent Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Argent Biopharma’s growth potential.
Argent Biopharma Revenue, EBIT and net profit per share
| Date | Argent Biopharma Revenue | Argent Biopharma EBIT | Argent Biopharma Net Income |
|---|---|---|---|
| 2025e | 19.19 M undefined | -1.92 M undefined | -2.39 M undefined |
| 2024 | 891,100 undefined | -18.04 M undefined | -17.53 M undefined |
| 2023 | 3.39 M undefined | -15.21 M undefined | -20.82 M undefined |
| 2022 | 4.73 M undefined | -14.42 M undefined | -20.35 M undefined |
| 2021 | 3 M undefined | -11.69 M undefined | -15.87 M undefined |
| 2020 | 2.08 M undefined | -11.28 M undefined | -19.36 M undefined |
| 2019 | 656,200 undefined | -8.71 M undefined | -8.58 M undefined |
| 2018 | 488,400 undefined | -6.86 M undefined | -8.25 M undefined |
| 2017 | 247,500 undefined | -6.95 M undefined | -8.14 M undefined |
| 2016 | 48,200 undefined | -2.42 M undefined | -6.16 M undefined |
| 2015 | 5,900 undefined | -847,800 undefined | -3.8 M undefined |
| 2014 | 10,000 undefined | -510,000 undefined | -5.34 M undefined |
| 2013 | 30,000 undefined | -740,000 undefined | -770,000 undefined |
| 2012 | 50,000 undefined | -290,000 undefined | -290,000 undefined |
| 2011 | 40,000 undefined | -210,000 undefined | 1.94 M undefined |
| 2010 | 2.74 M undefined | -1.31 M undefined | -3.18 M undefined |
| 2009 | 2.22 M undefined | -1.43 M undefined | -1.95 M undefined |
| 2008 | 1.93 M undefined | -1.62 M undefined | -1.89 M undefined |
| 2007 | 2.63 M undefined | -260,000 undefined | -280,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 2.63 M AUD | -260,000 AUD | -280,000 AUD |
| 2008 | 1.93 M AUD | -1.62 M AUD | -1.89 M AUD |
| 2009 | 2.22 M AUD | -1.43 M AUD | -1.95 M AUD |
| 2010 | 2.74 M AUD | -1.31 M AUD | -3.18 M AUD |
| 2011 | 40,000 AUD | -210,000 AUD | 1.94 M AUD |
| 2012 | 50,000 AUD | -290,000 AUD | -290,000 AUD |
| 2013 | 30,000 AUD | -740,000 AUD | -770,000 AUD |
| 2014 | 10,000 AUD | -510,000 AUD | -5.34 M AUD |
| 2015 | 5,900 AUD | -847,800 AUD | -3.8 M AUD |
| 2016 | 48,200 AUD | -2.42 M AUD | -6.16 M AUD |
| 2017 | 247,500 AUD | -6.95 M AUD | -8.14 M AUD |
| 2018 | 488,400 AUD | -6.86 M AUD | -8.25 M AUD |
| 2019 | 656,200 AUD | -8.71 M AUD | -8.58 M AUD |
| 2020 | 2.08 M AUD | -11.28 M AUD | -19.36 M AUD |
| 2021 | 3 M AUD | -11.69 M AUD | -15.87 M AUD |
| 2022 | 4.73 M AUD | -14.42 M AUD | -20.35 M AUD |
| 2023 | 3.39 M AUD | -15.21 M AUD | -20.82 M AUD |
| 2024 | 891,100 AUD | -18.04 M AUD | -17.53 M AUD |
| 2025e | 19.19 M AUD | -1.92 M AUD | -2.39 M AUD |
Argent Biopharma Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| REVENUE (M) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (k) |
| NET INCOME (k) |
| NET INCOME GROWTH (%) |
| SHARES (B) |
| DOCUMENTS |
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 3 | 0 | 19 |
| - | -50.00 | 100.00 | - | - | - | - | - | - | - | - | - | - | - | - | 100.00 | -25.00 | - | - |
| -150.00 | -300.00 | -150.00 | -150.00 | - | - | - | - | - | - | - | - | - | -150.00 | 50.00 | 25.00 | -100.00 | - | -15.79 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,000 | 1,000 | -3,000 | -3,000 | 0 |
| 0 | -1,000 | -1,000 | -3,000 | 1,000 | 0 | 0 | -5,000 | -3,000 | -6,000 | -8,000 | -8,000 | -8,000 | -19,000 | -15,000 | -20,000 | -20,000 | -17,000 | -2,000 |
| - | - | - | 200.00 | -133.33 | - | - | - | -40.00 | 100.00 | 33.33 | - | - | 137.50 | -21.05 | 33.33 | - | -15.00 | -88.24 |
| 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.09 | 0.16 | 0.28 | 0.6 | 0.97 | 1.13 | 1.21 | 1.38 | 0 | 0 | 0 | 0.04 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Argent Biopharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Argent Biopharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Argent Biopharma stock margins AU0000326647 · A2ACB6
The Argent Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Argent Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Argent Biopharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Argent Biopharma's sales revenue. A higher gross margin percentage indicates that the Argent Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Argent Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Argent Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Argent Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Argent Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Argent Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Argent Biopharma Margin History
| Argent Biopharma Gross margin | Argent Biopharma Profit margin | Argent Biopharma EBIT margin | Argent Biopharma Profit margin |
|---|---|---|---|
| 2025e | -419.58 % | -10 % | -12.48 % |
| 2024 | -419.58 % | -2,024.66 % | -1,967.3 % |
| 2023 | -88.65 % | -448.9 % | -614.7 % |
| 2022 | 34.73 % | -304.69 % | -430 % |
| 2021 | 36.7 % | -390.1 % | -529.69 % |
| 2020 | 8.4 % | -542.53 % | -931.28 % |
| 2019 | 45.66 % | -1,327.02 % | -1,307.42 % |
| 2018 | 75.57 % | -1,404.87 % | -1,688.43 % |
| 2017 | 36.12 % | -2,809.94 % | -3,290.67 % |
| 2016 | 68.88 % | -5,011.62 % | -12,774.07 % |
| 2015 | -419.58 % | -14,369.49 % | -64,369.49 % |
| 2014 | -419.58 % | -5,100 % | -53,400 % |
| 2013 | -419.58 % | -2,466.67 % | -2,566.67 % |
| 2012 | -419.58 % | -580 % | -580 % |
| 2011 | -419.58 % | -525 % | 4,850 % |
| 2010 | -419.58 % | -47.81 % | -116.06 % |
| 2009 | -419.58 % | -64.41 % | -87.84 % |
| 2008 | -419.58 % | -83.94 % | -97.93 % |
| 2007 | -419.58 % | -9.89 % | -10.65 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | -419.58 % | -9.89 % | -10.65 % |
| 2008 | -419.58 % | -83.94 % | -97.93 % |
| 2009 | -419.58 % | -64.41 % | -87.84 % |
| 2010 | -419.58 % | -47.81 % | -116.06 % |
| 2011 | -419.58 % | -525 % | 4,850 % |
| 2012 | -419.58 % | -580 % | -580 % |
| 2013 | -419.58 % | -2,466.67 % | -2,566.67 % |
| 2014 | -419.58 % | -5,100 % | -53,400 % |
| 2015 | -419.58 % | -14,369.49 % | -64,369.49 % |
| 2016 | 68.88 % | -5,011.62 % | -12,774.07 % |
| 2017 | 36.12 % | -2,809.94 % | -3,290.67 % |
| 2018 | 75.57 % | -1,404.87 % | -1,688.43 % |
| 2019 | 45.66 % | -1,327.02 % | -1,307.42 % |
| 2020 | 8.4 % | -542.53 % | -931.28 % |
| 2021 | 36.7 % | -390.1 % | -529.69 % |
| 2022 | 34.73 % | -304.69 % | -430 % |
| 2023 | -88.65 % | -448.9 % | -614.7 % |
| 2024 | -419.58 % | -2,024.66 % | -1,967.3 % |
| 2025e | -419.58 % | -10 % | -12.48 % |
Argent Biopharma Stock Sales Revenue, EBIT, Earnings per Share AU0000326647 · A2ACB6
The Argent Biopharma earnings per share therefore indicates how much revenue Argent Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Argent Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Argent Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Argent Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Argent Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Argent Biopharma Revenue, EBIT and net profit per share
| Date | Argent Biopharma Sales per Share | Argent Biopharma EBIT per share | Argent Biopharma Earnings per Share |
|---|---|---|---|
| 2025e | 0.32 undefined | 0 undefined | -0.04 undefined |
| 2024 | 0.02 undefined | -0.49 undefined | -0.47 undefined |
| 2023 | 1.16 undefined | -5.19 undefined | -7.1 undefined |
| 2022 | 1.84 undefined | -5.62 undefined | -7.93 undefined |
| 2021 | 1.57 undefined | -6.13 undefined | -8.33 undefined |
| 2020 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2019 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2018 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2017 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2016 | 0 undefined | -0 undefined | -0.01 undefined |
| 2015 | 0 undefined | -0 undefined | -0.01 undefined |
| 2014 | 0 undefined | -0 undefined | -0.03 undefined |
| 2013 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2012 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2011 | 0 undefined | -0.02 undefined | 0.16 undefined |
| 2010 | 0.34 undefined | -0.16 undefined | -0.39 undefined |
| 2009 | 0.28 undefined | -0.18 undefined | -0.24 undefined |
| 2008 | 0.24 undefined | -0.2 undefined | -0.24 undefined |
| 2007 | 0.36 undefined | -0.04 undefined | -0.04 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2007 | 0.36 AUD | -0.04 AUD | -0.04 AUD |
| 2008 | 0.24 AUD | -0.2 AUD | -0.24 AUD |
| 2009 | 0.28 AUD | -0.18 AUD | -0.24 AUD |
| 2010 | 0.34 AUD | -0.16 AUD | -0.39 AUD |
| 2011 | 0 AUD | -0.02 AUD | 0.16 AUD |
| 2012 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2013 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2014 | 0 AUD | -0 AUD | -0.03 AUD |
| 2015 | 0 AUD | -0 AUD | -0.01 AUD |
| 2016 | 0 AUD | -0 AUD | -0.01 AUD |
| 2017 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2018 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2019 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2020 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2021 | 1.57 AUD | -6.13 AUD | -8.33 AUD |
| 2022 | 1.84 AUD | -5.62 AUD | -7.93 AUD |
| 2023 | 1.16 AUD | -5.19 AUD | -7.1 AUD |
| 2024 | 0.02 AUD | -0.49 AUD | -0.47 AUD |
| 2025e | 0.32 AUD | 0 AUD | -0.04 AUD |
Argent Biopharma business model
Argent Biopharma is one of the most popular companies on Eulerpool.com.
Argent Biopharma Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Argent Biopharma historical P/E ratio, EBIT multiple, and P/S ratio
Argent Biopharma shares outstanding AU0000326647 · A2ACB6
The number of shares was Argent Biopharma in 2024 — This indicates how many shares 37.016 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Argent Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Argent Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Argent Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Argent Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2007 | 7.27 M Aktien |
| 2008 | 7.94 M Aktien |
| 2009 | 7.96 M Aktien |
| 2010 | 8.07 M Aktien |
| 2011 | 11.83 M Aktien |
| 2012 | 25.49 M Aktien |
| 2013 | 86.41 M Aktien |
| 2014 | 159.96 M Aktien |
| 2015 | 282.81 M Aktien |
| 2016 | 603.56 M Aktien |
| 2017 | 966.34 M Aktien |
| 2018 | 1.13 B Aktien |
| 2019 | 1.21 B Aktien |
| 2020 | 1.38 B Aktien |
| 2021 | 1.91 M Aktien |
| 2022 | 2.57 M Aktien |
| 2023 | 2.93 M Aktien |
| 2024 | 37.02 M Aktien |
| 2025e | 37.02 M Aktien |
Unfortunately, there are currently no price targets and forecasts available for Argent Biopharma.
Argent Biopharma shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 14.12303 % | Oak Capital Partners LLC | 8,370,718 | 8,370,718 | 9/6/2024 |
| 8.92917 % | Zomer (Roby Reuven) | 5,292,321 | 4,000,000 | 10/15/2024 |
| 6.60336 % | Group Capital Llc | 3,913,812 | 3,913,812 | 9/6/2024 |
| 5.74492 % | Safren (David) | 3,405,016 | 3,405,016 | 9/6/2024 |
| 3.76392 % | Bierman (Shlomie) | 2,230,874 | 2,230,874 | 9/6/2024 |
| 3.30168 % | Margareten (Isamar) | 1,956,906 | 1,956,906 | 9/6/2024 |
| 3.26135 % | Shimony (Shachar) | 1,933,000 | 1,863,500 | 9/6/2024 |
| 2.77341 % | Safren (Yaakov) | 1,643,802 | 1,643,802 | 9/6/2024 |
| 2.73844 % | Jacob (Goldstein) | 1,623,072 | 1,623,072 | 9/6/2024 |
| 2.70738 % | Drucker (Yoram) | 1,604,664 | 1,604,664 | 9/6/2024 |
1
2
3
Argent Biopharma Executives and Management Board
Mr. Roby Zomer
Argent Biopharma Chief Executive Officer, Managing Director, Executive Director (since 2016)
Compensation 629,362
Ms. Yifat Steuer
Argent Biopharma Deputy Chief Executive Officer, Chief Operating Officer
Mr. Igor Bluvstein
Argent Biopharma Chief Financial Officer
Mr. Robert Clements
Argent Biopharma Chief Commercial Officer
Mr. Rowan Harland
Argent Biopharma Company Secretary
1
2
Most common questions regarding Argent Biopharma
What is the P/S ratio of Argent Biopharma 2025?
The P/S cannot be calculated for Argent Biopharma currently.
What is the Quality Investing of Argent Biopharma?
The Quality Investing for Argent Biopharma is 8/10.
What is the revenue of Argent Biopharma 2025?
The expected Argent Biopharma revenue is 19.19 M AUD.
How high is the profit of Argent Biopharma 2025?
The expected Argent Biopharma profit is -2.39 M AUD.
What is the business model of Argent Biopharma
No history available for Argent Biopharma.
What is the Argent Biopharma dividend?
Argent Biopharma pays a dividend of 0 AUD distributed over payouts per year.
How often does Argent Biopharma pay dividends?
The dividend cannot currently be calculated for Argent Biopharma or the company does not pay out a dividend.
What is the Argent Biopharma ISIN?
The ISIN of Argent Biopharma is AU0000326647.
What is the Argent Biopharma WKN?
The WKN of Argent Biopharma is A2ACB6.
What is the Argent Biopharma ticker?
The ticker of Argent Biopharma is RGT.AX.
How much dividend does Argent Biopharma pay?
Over the past 12 months, Argent Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Argent Biopharma is expected to pay a dividend of 0 AUD.
What is the dividend yield of Argent Biopharma?
The current dividend yield of Argent Biopharma is .
When does Argent Biopharma pay dividends?
Argent Biopharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Argent Biopharma?
Argent Biopharma paid dividends every year for the past 0 years.
What is the dividend of Argent Biopharma?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Argent Biopharma located?
Argent Biopharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Argent Biopharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Argent Biopharma from 4/26/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 4/26/2025.
When did Argent Biopharma pay the last dividend?
The last dividend was paid out on 4/26/2025.
What was the dividend of Argent Biopharma in the year 2024?
In the year 2024, Argent Biopharma distributed 0 AUD as dividends.
In which currency does Argent Biopharma pay out the dividend?
The dividends of Argent Biopharma are distributed in AUD.
Argent Biopharma stock
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Argent Biopharma
Country
Australia 🇦🇺
Currency
AUD
Initial public offering
Dec 21, 2006
GOSIN
Global Open Securities Identification Number
Cusip
Q6074E133
Market capitalization
Quality Investing
8 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Argent Biopharma Peer Group
Argent Biopharma Eulerpool News
Argent Biopharma News
Argent Biopharma Ticker
| Stock Exchange | Argent Biopharma Ticker |
|---|---|
| ASX | MXC.AX |
| FRANKFURT | H5O.F |
| LONDON | MXC.L |
| LONDON STOCK EXCHANGE | MXC.L |
| MUNICH | H5O.MU |
All fundamentals about Argent Biopharma
Our stock analysis for Argent Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Argent Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
Argent Biopharma Revenue- Argent Biopharma Net Income
- Argent Biopharma P/E
- Argent Biopharma P/S
- Argent Biopharma EBIT
- Argent Biopharma Dividend
- Argent Biopharma Stocks
- Argent Biopharma Market capitalization
- Argent Biopharma Debt
- Argent Biopharma Liabilities
- Argent Biopharma Equity
- Argent Biopharma AAQS
- Argent Biopharma Employees
- Argent Biopharma ROE
- Argent Biopharma ROA
- Argent Biopharma ROCE